AngioDynamics, Inc. (NASDAQ:ANGO) Shares Acquired by Cubist Systematic Strategies LLC

Cubist Systematic Strategies LLC lifted its position in AngioDynamics, Inc. (NASDAQ:ANGO) by 15.1% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 226,503 shares of the medical instruments supplier’s stock after acquiring an additional 29,669 shares during the period. Cubist Systematic Strategies LLC owned 0.57% of AngioDynamics worth $1,370,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Fund 1 Investments LLC acquired a new position in shares of AngioDynamics in the fourth quarter valued at about $3,896,000. ADAR1 Capital Management LLC acquired a new position in AngioDynamics in the 4th quarter worth approximately $1,042,000. Kennedy Capital Management LLC raised its position in AngioDynamics by 425.0% during the 1st quarter. Kennedy Capital Management LLC now owns 190,236 shares of the medical instruments supplier’s stock worth $1,117,000 after buying an additional 154,002 shares during the last quarter. First Eagle Investment Management LLC acquired a new stake in AngioDynamics during the 2nd quarter valued at approximately $1,321,000. Finally, Acadian Asset Management LLC boosted its holdings in shares of AngioDynamics by 11.9% in the 1st quarter. Acadian Asset Management LLC now owns 1,012,186 shares of the medical instruments supplier’s stock valued at $5,940,000 after acquiring an additional 107,764 shares during the last quarter. Hedge funds and other institutional investors own 89.43% of the company’s stock.

Analyst Ratings Changes

ANGO has been the subject of a number of research reports. HC Wainwright restated a “buy” rating and set a $14.00 target price on shares of AngioDynamics in a research report on Friday, September 20th. Canaccord Genuity Group lowered their target price on AngioDynamics from $18.00 to $13.00 and set a “buy” rating on the stock in a research note on Wednesday, July 17th. One analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat, AngioDynamics has a consensus rating of “Moderate Buy” and a consensus price target of $12.25.

AngioDynamics Stock Down 1.9 %

ANGO stock opened at $7.63 on Wednesday. AngioDynamics, Inc. has a 52-week low of $5.26 and a 52-week high of $8.25. The firm has a market cap of $305.62 million, a P/E ratio of -1.57 and a beta of 0.65. The company’s 50-day simple moving average is $7.52 and its 200-day simple moving average is $6.60.

AngioDynamics (NASDAQ:ANGO) last issued its quarterly earnings data on Tuesday, July 16th. The medical instruments supplier reported ($0.06) EPS for the quarter, beating the consensus estimate of ($0.17) by $0.11. The company had revenue of $71.00 million for the quarter, compared to analyst estimates of $70.86 million. AngioDynamics had a negative return on equity of 4.91% and a negative net margin of 61.55%. AngioDynamics’s quarterly revenue was down 22.1% compared to the same quarter last year. During the same period last year, the company earned $0.02 earnings per share. On average, analysts anticipate that AngioDynamics, Inc. will post -0.41 earnings per share for the current fiscal year.

AngioDynamics Profile

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.